By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Summit Corporation 

London      United Kingdom
Phone: n/a Fax: n/a



Company News
Summit Corporation Awarded BARDA Contract Worth Up To $62 Million To Support Development Of Ridinilazole For CDI 9/11/2017 10:53:40 AM
Summit Corporation Files Registration Statement For Proposed U.S. Public Offering And Applies For NASDAQ Listing 2/2/2015 12:28:18 PM
Summit Corporation Appoints Erik Ostrowski As Chief Financial Officer 6/23/2014 2:26:20 PM
Summit Corporation Announces FDA Clearance Of IND Application For Phase 2 Study Of SMT19969 To Treat C. Difficile Infection 3/18/2014 9:15:51 AM
Summit Corporation Announces First Patient Dosed In A Phase 1b Clinical Trial Of Smt C1100 For Treatment Of Duchenne Muscular Dystrophy 12/9/2013 11:07:48 AM
Summit Corporation And The University of Oxford Enter Strategic Alliance To Develop Treatments For Duchenne Muscular Dystrophy 11/25/2013 12:22:00 PM
Summit Corporation Awarded £2.4 Million From the UK Biomedical Catalyst Fund to Support the Development of DMD Therapy 7/31/2013 10:52:28 AM
Summit Corporation Achieves Clinical Milestone Triggering £740,000 Payment From Wellcome Trust to Fund Novel C. Difficile Antibiotic 6/17/2013 9:03:49 AM
Summit Corporation Outlines Clinical Development Plans for Utrophin Modulator Program for Duchenne Muscular Dystrophy 3/21/2013 12:10:04 PM
Summit Corporation Forms Advisory Board to Support Development of Duchenne Muscular Dystrophy Program 2/13/2013 1:04:35 PM